It's time to get out there again and re-connect, and SmartTRAK is excited to be attending ISASS21, the International Society for the Advancement of Spine Surgery's 21st annual conference, at the Loews Miami Beach Hotel in South Beach Miami, May 13-15.
SmartTRAK will be represented by Julianne Burns, General Manager, Spine. Please contact us if you would like a meeting.
Click to read some recent SmartTRAKanalysis articles by Julianne that were featured on the blog:
Like the ball whirling around a casino roulette wheel, COVID-19 sent the US Joint Fluid Market players bouncing and spinning off widely, with some landing the year as winners, and others not so much.
Once again COVID-19 sent players spinning at dizzying speed around the roulette wheel, all in hopes that Lady Luck would let them land unscathed for Q420. With the continued pressure from COVID impacting recovery of the healthcare system and business operations, including the US Joint Fluid Replacement, total revenue for Q420 finished lower vs Q419, according to SmartTRAK Financial Dashboard.
Among the many topics covered in the comprehensive Q420/FY20 US Joint Fluid Market Recap* are:
We are excited to announce the addition of the full market view of Orthopedic Pediatrics (US) to the SmartTRAK platform, featuring 3 modules covering Pediatric Trauma, Pediatric Extremities and Pediatric Spine!
Coverage includes:
Aure Bruneau, CEO of Stimwave, discusses his vision for the Company and taking peripheral nerve stimulation to the next level in an interview with SmartTRAK
Since starting as CEO of Stimwave in April 2020, Aure Bruneau has brought a new vision, energy and focus to the Company. In the last 12 months, the former Zimmer Biomet executive has been positioning Stimwave for growth, building a high performing team and rebuilding the foundation of the Company, touching almost every aspect of the business, including regulatory, quality, manufacturing operations, marketing, IT, compliance and R&D. Strategically, Bruneau has refined the Company’s spinal cord stimulation (SCS) strategy and shifted efforts toward peripheral nerve stimulation (PNS) where he believes the technology will have a more meaningful impact and a market opportunity as big as the existing SCS market. In fact, he estimates the PNS opportunity to be at least $1.5 billion to treat chronic pain just for selected musculoskeletal indications (shoulders, knees, feet, ankles and the SI joint).
Looking ahead, Stimwave is planning to launch new products and a series of clinical trials in 2021 to validate a new standard of care that will help take the Company’s PNS platform to the next level and help drive future growth.
To find out more, click on the following video (26:35 min) and listen to SmartTRAK’s interview with Bruneau recorded recently via Uberconference. A transcript of the complete interview is also available below.
SmartTRAK is pleased to announce the addition of the Deep Brain Stimulation (DBS) module to our business intelligence platform. The DBS module will provide real-time news and analysis of the US market for Deep Brain Stimulation, including an in-depth overview of the market and expert insight into the latest research, trends and innovation in DBS.
"SmartTRAK is excited to offer this detailed analysis of the US DBS Market. By providing sophisticated market modeling and real-time monitoring of the competitive landscape, my goal is to provide must-have data and unparalleled insight that will help subscribing partners make informed strategic decisions and create innovative solutions that will ultimately improve patient care and drive results." Anne Staylor, SmartTRAK GM, Strategic Alignment & Neuro Therapies.
With jockeys and their racehorses out of the gates to make up for the losses during H120, a resurge of COVID cases muddied the track again, slowing the finish to the 2020 Derby.
If the US Orthobio Market was off racing again in Q320, the racetrack got a bit muddy with a resurgence of positive COVID-19 cases, which halted or placed restrictions on elective procedures in some US states. Spine procedure volumes were particularly affected by the renewed restrictions in Q420, which had a domino effect of negatively impacting the Bone Replacement segment for Q4 and FY20, respectively.
Among the many topics covered in the comprehensive Q420/FY20 US Orthobio Market Recap* are:
A year of turbulence as COVID-19 affects the WW Advanced Wound Care market at different times and in a variety of ways throughout the year.
For FY20, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was down -1.9% YoY. Q420 grew +1.0%, reflecting the gradual recovery in the market.
Among the many topics covered in the comprehensive Q420/FY20 Advanced Wound Care Market Recap* are:
SmartTRAK outlines consequences COVID-19 is expected to have on the European Trauma & Extremities Market
Twenty-five years of orthopedic business planning has taught me to monitor certain non-business factors when setting goals. Trends in weather patterns, age demographics, lifestyle and activities can have a direct influence on market growth. In 2020, the COVID-19 pandemic negatively impacted the European market with the shutdown of various countries and the ensuing changes in lifestyle such as reduced travel, work and sporting activities. In 2020, SmartTRAK predicted the European Trauma market fell by around 25% with extremities at nearly -50% in the midst of COVID-19 lockdowns. Similar market pressures are also expected during 2021.
Anticipated growth for Q4 was weakened by a resurgence of COVID-19 and was not enough to sustain growth with FY20 ending at -3.3% YoY decline.
For FY20, according SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access (VA) Adjunct Products market was down -3.3% YoY, while Q420 revenue was up +1.2% YoY.
The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.
Among the many topics covered in the comprehensive Q420/FY20 Infection Prevention: US Vascular Access Adjunct Market* are:
Despite market challenges due to the COVID-19 pandemic, 2020 was a game-changing year for enabling technology for orthopedic surgery with robotics hitting an inflection point in acceptance, with record placements in Q420, and enabling technology across the entire continuum of care making significant inroads.
In Q420, MAKO* robot demand drove much of the 12.3% growth in Stryker’s* US Ortho Other segment. In 2020, MAKO’s installed base grew by 33%, and in Q420 hit a milestone of > 100 system installations at major teaching institutions, ASCs and in competitive accounts in the quarter. In fact, according to the Company, MAKO is now available in ~50% of fellowship programs at teaching institutions in US, as well as some in Europe, which will help the transition to standard of care. Stryker noted that new market entrants (Zimmer Biomet’s* ROSA*, Smith & Nephew’s* CORI* and DePuy Synthes’* VELYS*) have not slowed MAKO momentum.
Among the many topics covered in the comprehensive Q420/FY20 CAS Ortho Market Recap* are:
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution that networks an entire organization with real-time market data and analysis, fostering an innovative and collaborative approach to market strategy while driving better decisions. SmartTRAK, used by leading orthopedic and wound care companies, transforms the delivery of healthcare business information into a cost-effective solution for life science corporations to increase proficiency, improve productivity and reduce cost.